Armistice Capital LLC Takes Position in Danaher Corporation $DHR

Key Points

• Armistice Capital LLC has acquired 80,992 shares of Danaher Corporation, valued at approximately $16.6 million, as reported in their recent SEC filing.
• Multiple institutional investors have significantly increased their stakes in Danaher, with MGO One Seven LLC's holdings growing by 485.7% in the 1st quarter.
• Danaher reported a 14.21% net margin and topped earnings estimates with $1.80 EPS for the last quarter, exceeding the consensus estimate of $1.64.

Armistice Capital LLC acquired a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 80,992 shares of the conglomerate's stock, valued at approximately $16,603,000.

Other institutional investors also recently made changes to their positions in the company. MGO One Seven LLC grew its stake in shares of Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after buying an additional 20,813 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new position in shares of Danaher during the 1st quarter valued at $539,000. Horizon Financial Services LLC lifted its holdings in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after acquiring an additional 8,160 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc lifted its holdings in shares of Danaher by 6.1% during the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 34,763 shares of the conglomerate's stock valued at $7,126,000 after acquiring an additional 2,009 shares in the last quarter. Finally, EFG Asset Management Americas Corp. lifted its holdings in shares of Danaher by 13.1% during the 1st quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock valued at $7,396,000 after acquiring an additional 4,191 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on DHR shares. Wells Fargo & Company reduced their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Barclays restated an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Guggenheim reiterated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 11.10% of the company's stock.

Danaher Price Performance

DHR opened at $206.09 on Friday. The company has a 50-day moving average of $201.65 and a 200-day moving average of $199.49. The company has a market capitalization of $147.57 billion, a P/E ratio of 43.85, a PEG ratio of 2.87 and a beta of 0.73. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company's revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.